SAFETY, TOLERABILITY, AND PHARMACOKINETIC INTERACTIONS OF ATAZANAVIR

阿扎那韦的安全性、耐受性和药代动力学相互作用

• 批准号: 7718628
• 负责人: SUSAN L KOLETAR
• 金额: $ 0.7万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-12-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7718628
• 关键词: Atazanavir; Blood; Computer Retrieval of Information on Scientific Projects Database; Drug Kinetics; Drug usage; Funding; Grant; HIV; Infection; Institution; Lung; Measures; Participant; Persons; Pharmaceutical Preparations; Process; Research; Research Personnel; Resources; Rifampin; Safety; Source; Time; Tuberculosis; United States National Institutes of Health

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is being done to find out the levels of atazanavir, a drug used to treat HIV, and rifampin, a drug used to treat the lung infection tuberculosis (TB), are processed in the blood of persons who take these drugs at the same time. This will be done by measuring these drugs in the participants blood at different times after the participant's take the drugs. This study will also examine the safety of these drugs when taken at the same time and see how well they are tolerated.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这项研究的目的是查明同时服用阿扎那韦（一种用于治疗艾滋病毒的药物）和利福平（一种用于治疗肺部感染结核病的药物）的人血液中的含量。这将通过在参与者服用药物后的不同时间测量参与者血液中的这些药物来完成。 这项研究还将检查这些药物同时服用的安全性，并观察它们的耐受性。